|
|
|
Insider
Information: |
Mueller Peter |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
311,837 |
|
Indirect Shares
|
25,571 |
|
|
Direct
Value |
$68,363,700 |
|
|
Indirect Value
|
$12,144,946 |
|
|
Total
Shares |
337,408 |
|
|
Total
Value |
$80,508,646 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Global R&D, CSO |
2014-06-16 |
143,517 |
2014-06-16 |
25,571 |
Premium* |
|
Bioxcel Therapeutics Inc |
BTAI |
Director |
2019-08-23 |
168,320 |
2018-12-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
141 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 3 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2009-03-16 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
99,756 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2009-03-16 |
4 |
AS |
$28.05 |
$68,250 |
D/D |
(2,400) |
97,356 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2009-04-15 |
4 |
AS |
$26.98 |
$64,752 |
D/D |
(2,400) |
129,670 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Drug Innov.& Realiz, CSO |
|
2009-04-15 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
132,070 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-05-15 |
4 |
AS |
$28.56 |
$68,544 |
D/D |
(2,400) |
116,874 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-05-15 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
119,274 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-06-15 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
119,274 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-06-15 |
4 |
AS |
$31.02 |
$74,448 |
D/D |
(2,400) |
116,874 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-07-15 |
4 |
AS |
$32.88 |
$78,912 |
D/D |
(2,400) |
116,874 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Global R&D, CSO |
|
2009-07-15 |
4 |
OE |
$9.69 |
$23,256 |
D/D |
2,400 |
119,274 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-15 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-15 |
4 |
AS |
$47.28 |
$118,716 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-05-16 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-05-16 |
4 |
AS |
$55.44 |
$142,554 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-06-15 |
4 |
AS |
$46.50 |
$116,698 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-06-15 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-07-15 |
4 |
AS |
$50.68 |
$126,700 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-07-15 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2013-12-12 |
4 |
AS |
$65.48 |
$189,892 |
D/D |
(2,900) |
141,500 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-02-03 |
4 |
AS |
$40.07 |
$154,029 |
D/D |
(3,844) |
111,004 |
0 |
- |
|
BTAI |
Bioxcel Therapeutics Inc |
Director |
|
2018-12-04 |
4 |
B |
$5.09 |
$20,544 |
D/D |
4,007 |
149,525 |
2.39 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-05-07 |
4 |
AS |
$35.78 |
$225,571 |
D/D |
(6,271) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-06-15 |
4 |
AS |
$56.37 |
$366,405 |
D/D |
(6,500) |
132,316 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-06-15 |
4 |
OE |
$16.32 |
$106,080 |
D/D |
6,500 |
138,816 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-07-16 |
4 |
OE |
$16.32 |
$106,080 |
D/D |
6,500 |
138,816 |
0 |
- |
|
141 Records found
|
|
Page 3 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|